Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03908255 | Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma(BCAA in HCC) | withdrawn | Phase 2 | 0 | Louisiana State University Health Sciences Center in New OrleansOTHER | 1 | Jan 28, 2022 |
| clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04001101 | Anti-PD-1 +/- RT for MSI-H Solid Tumors | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03661047 | OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer(OMICC) | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Nov 17, 2021 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT01960023 | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | NSABP Foundation IncNETWORK | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04430985 | FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer(IMMUNOX) | withdrawn | Phase 2 | 0 | Dorte NielsenOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04620473 | Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | withdrawn | Phase 2 | 0 | Shanghai Minimally Invasive Surgery CenterOTHER | 0 | Sep 28, 2021 | clinicaltrials |
| NCT01915472 | A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma(TheraBionics) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04186156 | A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Karus Therapeutics LimitedINDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03484962 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03524274 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03554395 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT00020774 | SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2020 | clinicaltrials |
| NCT00882765 | Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03768531 | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Apr 13, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03688230 | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.(AMELION) | withdrawn | Phase 2 | 0 | SFJ Pharmaceuticals X, LTD.INDUSTRY | 0 | Mar 18, 2020 | clinicaltrials |
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 16, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer(DYNAMIC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03323424 | Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers(IRAM) | withdrawn | Phase 2 | 0 | Institut de Cancérologie de la LoireOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT01741038 | AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | withdrawn | Phase 2 | 0 | A2 Healthcare Taiwan CorporationINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection | withdrawn | Phase 2 / Phase 3 | 0 | Shi MingOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2022source: clinicaltrials